Arthur J.E. Child Comprehensive Cancer Centre

Running trials

• Not yet recruiting

  Alberta Cancer Exercise Dose in Colorectal Cancer

  NCT07913906· Phase 2· University of Calgary· Source

• Recruiting

  GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

  NCT07297667· Phase 1· Canadian Cancer Trials Group· Source

• Recruiting

  Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy

  NCT07341191· Phase 2· Canadian Cancer Trials Group· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07518186· Phase 3· Janssen Research & Development, LLC· Source

• Not yet recruiting

  Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)

  NCT05128734· Phase 2· AHS Cancer Control Alberta· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

  NCT07221149· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07258511· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

  NCT07216703· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

  NCT07195682· Phase 1· Bristol-Myers Squibb· Source

• Recruiting

  Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT07222566· Phase 3· Pfizer· Source

• Recruiting

  A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

  NCT07100080· Phase 2/3· Bristol-Myers Squibb· Source

• Active, not recruiting

  A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

  NCT07076121· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  NCT07213804· Phase 3· Eli Lilly and Company· Source

• Recruiting

  STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma

  NCT06880523· Phase 2· Canadian Cancer Trials Group· Source

• Recruiting

  A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

  NCT06988488· Phase 1/2· Celgene· Source

• Recruiting

  A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

  NCT06989437· Phase 2/3· Pfizer· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  NCT07144280· Phase 3· Pfizer· Source

• Recruiting

  A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

  NCT07164443· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

  NCT06966453· Phase 1/2· Pfizer· Source

• Recruiting

  A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  NCT06852222· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

  NCT06820463· Phase 2· AbbVie· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

  NCT06824467· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

  NCT06790693· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery)

  NCT05407987· Phase 3· AHS Cancer Control Alberta· Source

• Recruiting

  Palliative Steroeotactic Body Radiotherapy vs Palliative Standard Radiotherapy in Patients With Advanced Head and Neck Cancer

  NCT06641791· Phase 3· Canadian Cancer Trials Group· Source

• Recruiting

  A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

  NCT06615479· Phase 3· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• Recruiting

  Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

  NCT06806033· Phase 2· Hoffmann-La Roche· Source

• Active, not recruiting

  CAR T Therapy With GCAR1 for Relapsed Alveolar Soft Part Sarcoma

  NCT06813417· Early phase 1· University of Calgary· Source

• Recruiting

  CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

  NCT06208735· Phase 1· British Columbia Cancer Agency· Source

• Recruiting

  Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes

  NCT06439225· Phase 3· Canadian Cancer Trials Group· Source

• Active, not recruiting

  Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

  NCT06691984· Phase 3· Amgen· Source

• Active, not recruiting

  A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

  NCT06551324· Phase 3· Pfizer· Source

• Recruiting

  A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

  NCT06662786· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

  NCT06388564· Phase 2· Incyte Corporation· Source

• Active, not recruiting

  Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)

  NCT05417789· Phase 3· SynOx Therapeutics Limited· Source

• Recruiting

  Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  NCT05554406· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  NCT05554393· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

  NCT06422806· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

  NCT06246916· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

  NCT06486441· Phase 3· Gilead Sciences· Source

• Recruiting

  Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

  NCT06252649· Phase 3· Amgen· Source

• Active, not recruiting

  Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

  NCT06456346· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

  NCT06393374· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  NCT05564390· Phase 2· National Cancer Institute (NCI)· Source

• Active, not recruiting

  A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

  NCT06360354· Phase 1· Amgen· Source

• Recruiting

  Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

  NCT06297226· Phase 2· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• Recruiting

  A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

  NCT06121843· Phase 1· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• Active, not recruiting

  A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

  NCT06012435· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

Showing 50 of 122.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple myeloma9 recruiting
• Colorectal cancer5 recruiting
• Acute myeloid leukaemia4 recruiting
• Childhood cancers4 recruiting
• Bladder cancer3 recruiting
• Lung cancer3 recruiting
• Metastatic breast cancer3 recruiting
• Myeloproliferative neoplasms3 recruiting
• Ovarian cancer3 recruiting
• Triple-negative breast cancer3 recruiting
• Chronic lymphocytic leukaemia2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Hodgkin lymphoma2 recruiting
• Kidney cancer2 recruiting
• Mantle cell lymphoma2 recruiting
• Myelodysplastic syndromes2 recruiting
• Neuroendocrine tumours2 recruiting
• Pancreatic cancer2 recruiting
• Prostate cancer2 recruiting
• Sarcoma2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Brain metastases1 recruiting
• Cervical cancer1 recruiting
• Endometrial cancer1 recruiting
• Follicular lymphoma1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Glioblastoma1 recruiting
• Head and neck cancer1 recruiting
• Iron deficiency anaemia1 recruiting
• Liver and biliary tract cancer1 recruiting
• Melanoma1 recruiting

Closed trials

• Completed

  A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

  NCT06618001· Phase 1· Janssen Research & Development, LLC· Source

• Completed

  Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT06058793· Phase 3· Boehringer Ingelheim· Source

• Completed

  GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma

  NCT06827886· Early phase 1· AHS Cancer Control Alberta· Source

• Terminated

  PSMA-PET/CT Registry

  NCT05709535· AHS Cancer Control Alberta· Source

• Terminated

  A Research Study to Collect Patient Reported Outcomes Using Electronic Surveys

  NCT04990895· AHS Cancer Control Alberta· Source

• Terminated

  MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

  NCT05090566· Phase 2· Pfizer· Source

• Terminated

  Pre- Versus Post-operative SRS for Resectable Brain Metastases

  NCT04474925· Phase 3· AHS Cancer Control Alberta· Source

• Completed

  MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

  NCT04649359· Phase 2· Pfizer· Source

• Completed

  Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

  NCT04428151· Phase 2· Merck Sharp & Dohme LLC· Source

• Terminated

  A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment

  NCT04268199· Phase 2· AHS Cancer Control Alberta· Source

• Completed

  Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring

  NCT04037254· Phase 1/2· NRG Oncology· Source

• Completed

  A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

  NCT03652064· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

  NCT03301220· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

  NCT03201965· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

  NCT03274687· Phase 3· NRG Oncology· Source

• Completed

  A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

  NCT02908672· Phase 3· Hoffmann-La Roche· Source

• Completed

  Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

  NCT02807636· Phase 3· Hoffmann-La Roche· Source

• Completed

  Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

  NCT02242942· Phase 3· Hoffmann-La Roche· Source

• Completed

  Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival

  NCT02364557· Phase 2/3· NRG Oncology· Source

• Completed

  Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

  NCT01935934· Phase 2· National Cancer Institute (NCI)· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Kidney cancer29 works · 6 trials